286 related articles for article (PubMed ID: 35493463)
1. The Pan-Cancer Landscape of Crosstalk Between TRP Family and Tumour Microenvironment Relevant to Prognosis and Immunotherapy Response.
Wu G; He M; Yin X; Wang W; Zhou J; Ren K; Chen X; Xue Q
Front Immunol; 2022; 13():837665. PubMed ID: 35493463
[TBL] [Abstract][Full Text] [Related]
2. Pan-Cancer Analysis of the TRP Family, Especially TRPV4 and TRPC4, and Its Expression Correlated with Prognosis, Tumor Microenvironment, and Treatment Sensitivity.
Chen Z; Zhao Y; Tian Y; Cao R; Shang D
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830651
[TBL] [Abstract][Full Text] [Related]
3. The Pan-Cancer Multi-Omics Landscape of FOXO Family Relevant to Clinical Outcome and Drug Resistance.
Xie J; Zhang J; Tian W; Zou Y; Tang Y; Zheng S; Wong CW; Deng X; Wu S; Chen J; Mo Y; Xie X
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555288
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive pan-cancer analysis of YBX family reveals YBX2 as a potential biomarker in liver cancer.
Yuan Z; Li B; Liao W; Kang D; Deng X; Tang H; Xie J; Hu D; Chen A
Front Immunol; 2024; 15():1382520. PubMed ID: 38698857
[TBL] [Abstract][Full Text] [Related]
5. The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer.
Sun X; Zhang Z; Wang Z; Xie R; Yi C; Liu H; Chi X; Li T; Liu H; Han Y; Pang X; Cui Y; Liu Z
Front Immunol; 2022; 13():1033967. PubMed ID: 36479101
[TBL] [Abstract][Full Text] [Related]
6. Immunological role and prognostic value of the SKA family in pan-cancer analysis.
Li Z; Huang L; Li J; Yang W; Li W; Long Q; Dai X; Wang H; Du G
Front Immunol; 2023; 14():1012999. PubMed ID: 37180139
[TBL] [Abstract][Full Text] [Related]
7. IP-score correlated to endogenous tumour antigen peptide processing: A candidate clinical response score algorithm of immune checkpoint inhibitors therapy in multiple cohorts.
Wang Y; Yan K; Guo Y; Lu Y; Su H; Li H
Front Immunol; 2022; 13():1085491. PubMed ID: 36700205
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation.
Qin Y; Pan L; Qin T; Ruan H; Zhang Y; Zhang Y; Li J; Yang J; Li W
Front Immunol; 2022; 13():998266. PubMed ID: 36248785
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect.
Han X; Ye J; Huang R; Li Y; Liu J; Meng T; Song D
Front Immunol; 2022; 13():900273. PubMed ID: 36159856
[TBL] [Abstract][Full Text] [Related]
10. The circadian rhythm key gene
Wu G; Ren H; Hu Q; Ma H; Chen H; Zhou L; Xu K; Ding L
Front Immunol; 2023; 14():1115809. PubMed ID: 37275880
[TBL] [Abstract][Full Text] [Related]
11. Multi-Omics Pan-Cancer Analysis of Procollagen N-Propeptidase Gene Family of ADAMTS as Novel Biomarkers to Associate with Prognosis, Tumor Immune Microenvironment, Signaling Pathways, and Drug Sensitivities.
Chen Y; Xiao C; Fan Q; Zhang Y; Huang Q; Ou Y
Front Biosci (Landmark Ed); 2024 Apr; 29(4):151. PubMed ID: 38682182
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive analysis of PANoptosome to prognosis and immunotherapy response in pan-cancer.
Zhuang L; Sun Q; Huang S; Hu L; Chen Q
Sci Rep; 2023 Mar; 13(1):3877. PubMed ID: 36890219
[TBL] [Abstract][Full Text] [Related]
13. CDK16 as a potential prognostic biomarker correlated with an immunosuppressive tumor microenvironment and benefits in enhancing the effectiveness of immunotherapy in human cancers.
Qi J; Wu G; He M; Xu Y; Yang Z; Ding L; Wang Y; Zhang Z
Aging (Albany NY); 2024 Jan; 16(2):1879-1896. PubMed ID: 38261737
[TBL] [Abstract][Full Text] [Related]
14. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer analysis identifies the IRF family as a biomarker for survival prognosis and immunotherapy.
Xu HG; Chen C; Chen LY; Pan S
J Cell Mol Med; 2024 Feb; 28(3):e18084. PubMed ID: 38130025
[TBL] [Abstract][Full Text] [Related]
16. Fc Fragment of IgE Receptor Ig (FCER1G) acts as a key gene involved in cancer immune infiltration and tumour microenvironment.
Yang R; Chen Z; Liang L; Ao S; Zhang J; Chang Z; Wang Z; Zhou Y; Duan X; Deng T
Immunology; 2023 Feb; 168(2):302-319. PubMed ID: 36054819
[TBL] [Abstract][Full Text] [Related]
17. The pan-cancer multi-omics landscape of key genes of sialylation combined with RNA-sequencing validation.
Wu Z; Wang Z; Wu H; Zheng N; Huang D; Huang Z; Han H; Bao J; Xu H; Zhang R; Du Z; Wu D
Comput Biol Med; 2023 Nov; 166():107556. PubMed ID: 37801920
[TBL] [Abstract][Full Text] [Related]
18. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC).
Cao R; Yuan L; Ma B; Wang G; Tian Y
Cancer Immunol Immunother; 2021 Jan; 70(1):1-18. PubMed ID: 32617668
[TBL] [Abstract][Full Text] [Related]
19. Immunologic Gene Sets Reveal Features of the Tumor Immune Microenvironment and Predict Prognosis and Immunotherapy Response: A Pan-Cancer Analysis.
Pan H; Pan J; Li P; Wu J
Front Immunol; 2022; 13():858246. PubMed ID: 35493519
[TBL] [Abstract][Full Text] [Related]
20. Integrative analysis revealed a correlation of PIAS family genes expression with prognosis, immunomodulation and chemotherapy.
Zhang Q; Zhang J; Lan T; He J; Lei B; Wang H; Mei Z; Lv C
Eur J Med Res; 2024 Mar; 29(1):195. PubMed ID: 38528630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
